As serum FGF-21 levels in the HIV-uninfected population are elevated in conditions associated with increased cardiovascular risk, it is very plausible that serum FGF-21 elevation in anti-retroviral treated HIV infection may also be a marker of an adverse metabolic risk in this patient group. Here, FGF21 is linked to HIV infectious disease.